Compare Stocks

Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.

CIRCOR International, Inc. designs, manufactures, and distributes flow and motion control products in Europe, the Middle East, Africa, North America, and internationally. The company has a product portfolio of brands serving its customers' demanding applications. It operates through two segments, Aerospace & Defense and Industrial. The Aerospace & Defense segment manufactures and markets control valves, pumps, regulators, fluid controls, pneumatic valves and controls, electro-mechanical controls, electric motors, and other flow control products and subsystems; propeller pumps; actuation systems; MIL-spec butterfly valves and actuators; brushless DC motors; switches; and actuation components and sub-systems. Its products and services are used in the military and defense, commercial aerospace, business and general aviation, and general industrial markets, as well as serves aircraft manufacturers and tier 1 and tier 2 suppliers. This segment offers its products under the CIRCOR Aerospace, Aerodyne Controls, CIRCOR Bodet, CIRCOR Industria, CIRCOR Motors, Hale Hamilton, Leslie Controls, Portland Valve, and Warren Pumps brands. The Industrial segment provides 3 and 2 screw pumps, progressing cavity pumps, specialty centrifugal pumps, and gear metering pumps; automatic recirculation valves; engineered valves; positive displacement pumps; general service control valves; and top and bottom unheading devices and center feed devices for the end-users and original equipment manufacturers, as well as engineering, procurement, and construction companies. This segment offers its products under the Allweiler, DeltaValve, Houttuin, IMO Pump, IMO AB, Leslie Controls, RG Lawrence, RTK, Schroedahl, TapcoEnpro, Tushaco, and Zenith brands. The company markets its solutions directly and through various sales partners to approximately 14,000 customers in approximately 100 countries. CIRCOR International, Inc. was incorporated in 1999 and is headquartered in Burlington, Massachusetts.

Eaton Vance Municipal Income 2028 Term Trust is a closed ended fixed income mutual fund launched and managed by Eaton Vance Management. It invests in the fixed income markets. The fund invest in stocks of companies operating across the diversified sectors. It was previously known as Eaton Vance Municipal Income Term Trust. Eaton Vance Municipal Income 2028 Term Trust was formed on March 28, 2013 and is domiciled in the United States.

Novoheart Holdings Inc. operates as a stem cell biotechnology company in the United States. The company offers an array of next-generation human heart tissue prototypes. It provides MyHeart platform products, including human pluripotent stem cell-derived cardiomyocytes, human ventricular cardiac anisotropic sheet assays, and human ventricular cardiac tissue strips assays. The company also offers screening and phenotyping services; and consultation services, including mapping and designing preclinical studies that involve human embryonic or induced pluripotent stem cell-derived cardiomyocytes, prototyping custom bioreactor designs, and developing custom software for streamlining of screening platforms and analysis of acquired data. Novoheart Holdings Inc. has a collaboration with AstraZeneca to develop human-specific in vitro functional model of heart failure with preserved ejection fraction. The company is based in Vancouver, Canada.

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.